Industry News

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Mr. Dror Ben-Asher, RedHill’ s Chief Executive Officer, will present at the BIO Investor Forum 2016, on Tuesday, October 18, 2016, at 10:30 am PDT, at the Westin St."/>
RedHill Biopharma to Present at the BIO Investor Forum 2016
TransEnterix, Inc., a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robot at the Clinical Congress 2016 of the American College of Surgeons. The congress will be held on October 16-20, 2016 in Washington, DC."/>
TransEnterix to Feature Senhance™ Surgical Robot at American College of Surgeons Clinical Congress
HMS Holdings Corp revealed on Wednesday the addition of Alex Michael Azar II to its board of directors with immediate effect. Currently, Azar serves as president, Lilly USA LLC, the largest affiliate of Eli Lilly& Company. Most recently, Azar was employed as the deputy secretary and general counsel at the US Department of Health& Human Services."/>
HMS Holdings Corp names Alex Michael Azar II to board
Insys Therapeutics, Inc. today announced that its preliminary estimated revenues from Subsys ® for the third quarter of 2016 will be in the range of $54 million to $55 million. The Company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth.. Estimated revenues for the quarter reflect a decline in prescriptions as the Company continues to believe that the..."/>
Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the Third Quarter 2016
Danaher Corp., the companies said. Terms of the deal were not disclosed. Analysts put the purchase price at around USD 700 m."/>
Purification Consumables Firm Phenomenex Agrees to Danaher Buyout
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, today announced the appointment of Suzette Jaskie as Vice President Global Medical Affairs. This Smart News Release features multimedia. View the full release here:"/>
Corindus Vascular Robotics Appoints Suzette Jaskie Vice President Global Medical Affairs
Triple-S Management Corporation, a leading managed care company in Puerto Rico, today announced the star ratings for its Medicare Advantage plans from the Centers of Medicare and Medicaid Services for payment year 2018. The purpose of this rating system is to provide Medicare beneficiaries with information to compare the quality of care across different plans. The company's HMO offering increased from 3 to 4 stars overall and..."/>
Triple-S Management Corporation Awarded Four-Star Rating For Its HMO Offerings
Teleflex Incorporated announced today that financial results for the third quarter 2016 will be released before market open on Thursday, October 27, 2016. An investor conference call will be held at 8:00 a.m. on Thursday, October 27, 2016."/>
Teleflex Announces Third Quarter 2016 Earnings Conference Call Information
Anthem Medicare Membership Enrolled in Plans that Scored 4 Stars or Higher. INDIANAPOLIS---- Anthem Inc. has earned high Medicare Star Quality Ratings from the Centers for Medicare& Medicaid Services for its Medicare Advantage plans for 2017. In the most recent ratings released by CMS, nearly 51 percent of Anthem Medicare Advantage members will be enrolled in plans that achieved four stars or higher as compared with approximately 22 percent of members..."/>
Anthem Medicare Plans Score Significant Increases in 2017 Medicare Star Quality Ratings
BioTime, Inc., a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor Forum on Wednesday, October 19, 2016, at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time. The BIO Investor Forum is being held at the Westin St. Francis Hotel in San Francisco."/>
BioTime to Present at the BIO Investor Forum
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced that new clinical data from the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse ® IL-12, and Merck's KEYTRUDA ® in patients with unresectable metastatic melanoma and a low likelihood of..."/>
OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2 a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil..."/>
CMX157 Demonstrates 99% Viral Load Reduction in Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® in Hepatitis B Patients
Scientific Industries Inc. reported net income of $165,600 on net sales of $9,597,600, for the fiscal year ended June 30, 2016, compared to $8,700 on net sales of $7,848,400 for the fiscal year ended June 30, 2015.. The increased income and revenues resulted primarily from increased sales and profits due to a substantial order for catalyst research instruments in fiscal 2016, and lower operating expenses of the Company's benchtop laboratory equipment..."/>
Scientific Industries Reports Improved Results for Fiscal 2016
St. Jude Medical in the wake of news that hundreds of thousands of batteries in its top-selling product-- implantable defibrillators-- are vulnerable to a rare but serious defect that leaves them unable to save lives. Jude Medical stock was stable Wednesday, losing just 6 cents to close at $78.35 while the wider Standard& Poor's 500 was also flat."/>
St. Jude stock stable after heart device battery disclosure [Star Tribune (Minneapolis)]
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, today announced results from the exploratory clinical phase II study CiPRICS. The results clearly show that patients treated with CicloMulsion prior to open heart surgery experience no benefit compared to placebo in the prevention of acute kidney injury. As a result, NeuroVive will discontinue the development of CicloMulsion for AKI."/>
NeuroVive discontinues development of CicloMulsion for acute kidney injury
Casino Group: Q3 2016 Sales
Alliqua BioMedical Inc. based in Yardley, Pa. The move allows Soluble's 60 employees and some senior management to continue working as part of a larger company capable of taking the business's growth to the next level, Soluble Systems CEO Allan Staley said. "This is a combination of two companies to form a stronger, more viable, powerful..."/>
Homegrown Newport News biotech company to join up with partner for growth [Daily Press (Newport News, Va.)]
Mercury News Biz Break column [Mercury News]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology733 Articles
Consumer Discretionary627 Articles
Financials544 Articles
Health Care430 Articles
Industrials395 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at